Looking to list your PhD opportunities? Log in here.
This project is no longer listed on FindAPhD.com and may not be available.
Click here to search FindAPhD.com for PhD studentship opportunitiesAbout the Project
Cases of primary liver cancer, also known as hepatocellular cancer (HCC) are rising rapidly in the UK and new therapies are urgently needed. Immune therapy has shown promising results and in this project we want to explore the potential of using a specific immune cell called macrophages. Pre-cursor macrophages, called monocytes, are found in our blood circulation but they can leave the circulation and enter organs throughout the body. Macrophages are attractive as a target for immunotherapy as their behavior can be altered to attack tumours and they can also potentially acts as drug delivery agents because they can engulf particles and transport them to sites of disease. To help their delivery we are studying how macrophages can cross blood vessels through cells called endothelial cells. We will use cutting edge imaging and modelling to see how macrophages cross the liver endothelial cells in different physical environments of fluid flow and endothelial stiffness and assess how efficient this process is when macrophages are pre-loaded with cargo. This project will help understand the physical factors which control macrophages crossing the liver barrier and help to design new approaches to promote macrophage cell therapy for liver cancer.

Search suggestions
Based on your current searches we recommend the following search filters.
Check out our other PhDs in Birmingham, United Kingdom
Check out our other PhDs in United Kingdom
Start a New search with our database of over 4,000 PhDs

PhD suggestions
Based on your current search criteria we thought you might be interested in these.
Nanotechnologies for cancer: developing new polymer-drug conjugates for the treatment of a range of cancers
University of Reading
Cancer: Epigenetic therapy using microbubble-mediated drug delivery for colorectal cancer
University of Leeds
Polmorphisms in cytosolic drug metabolising enzymes: a combined proteomics and modelling approach to clinical impact
The University of Manchester